Monoclonal Gammopathy of Renal Significance: Consensus of Hematologists and Nephrologists of Russia on the Establishment of Nosology, Diagnostic Approach and Rationale for Clone Specific Treatment

Monoclonal gammopathy of renal significance (MGRS) is a new nosology in modern nephrology and oncohematology. MGRS is defined as kidney injury due to nephrotoxic monoclonal immunoglobulin produced by the B-cell line clone which does not reach the hematological criteria for specific treatment initiation. Monoclonal protein’s pathological effects on kidney parenchyma result in irreversible decline of kidney function till the end stage renal disease that in line with the position of International Consensus of hematologists and nephrologists determinates critical necessity for clone specific treatment in patients with MGRS despite the absence of hematological indications for treatment initiation. Main challenge of MGRS in Russian Federation is an inaccessibility of an in-time diagnostic and appropriate treatment for the great majority of patients due to the following reasons: i) limited knowledge about the MGRS among hematologists and nephrologists; ii) lack of necessary diagnostic resources in most healthcare facilities; iii) lack of approved clinical recommendations and medical economic standards for treatment of this pathological entity. Consensus document comprises the opinion of experts — leading nephrologists and hematologists of Russian Federation — on the problem of MGRS including the incoherence in nosology classification, diagnostics approach and rationale for clone specific treatment. Consensus document is based on conclusions and agreements reached during the conference of leading nephrologists and hematologists of Russia which was held in the framework of symposia «Plasma cell dyscrasias and lymphoproliferative diseases: modern approaches to therapy», 15-16 of March 2019, Pavlov First St-Petersburg State Medical University, St-Petersburg, Russia. The present Consensus is intended to define the principal practical steps to resolve the problem of MGRS in Russian Federation that are summarized as final clauses.

1. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120(22):4292–4295. doi: 10.1182/blood-2012-07-445304

2. Leung N, Bridoux F, Batuman V et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15(1):45–59. doi: 10.1038/s41581-018-0077-4

3. Kozlovskaya LV, Rameev VV, Kogarko IN et al. Renal lesions associated with monoclonal gammopathies of undetermined significance: clinical forms, mechanisms of development, approaches to treatment. Klin med 2016;94(12):892–901. (In Russ.) doi: 10.18821/0023-2149-201694-12-892-901

4. Khrabrova MS, Dobronravov VA, Smirnov AV. Kidney disease associated with monoclonal gammopathies: single-center study. Nephrology (Saint-Petersburg) 2018;22(6):38–46. (In Russ.) doi: 10.24884/1561-6274-2018-22-6-38-46

5. Zakharova EV, Stolyarevich ES. Kidney damage in lymphoproliferative and plasma cell disorders (one center experience). Almanac of Clinical Medicine 2014;(30):3–11. (In Russ.) doi: 10.18786/2072-0505-201430-3-11

6. Zakharova EV, Stolyarevich ES. Renal consequences of Lymphoproliferative Disorders and Monoclonal Gammopathy. Urol Nephrol Open Access 2015;2(4):47–55. doi: 10.15406/unoaj.2015.02.00047

7. Zand L, Nasr SH, Gertz MA et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma 2015;56(12):3357–3364. doi: 10.3109/10428194.2015

8. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12(7):1482–1492

9. Nasr SH, Valeri AM, Cornell LD et al. Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012;7:231–239

10. Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775–784

11. Steiner N, Gobel G, Suchecki P et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 2017;9(2):2344–2356. doi: 10.18632/oncotarget.23412

12. Kourelis TV, Nasr SH, Dispenzieri A et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 2016;91(11):1123–1128. doi: 10.1002/ajh.24528

13. Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015;88:1135–1143

14. Ziogas DC, Kastritis E, Terpos E, Roussou M et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma 2017;58(8):1832–1839. doi: 10.1080/10428194.2016.1267349

15. Gumber R, Cohen JB, Palmer MB et al. A clone-directed approach may improve diagnosis and treatment of proliferativeglomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94(1):199–205. doi: 10.1016/j.kint.2018.02.020

16. Mendeleeva LP, Votyakova OM, Pokrovskaya OS et al. National clinical recommendations on diagnosis and treatment of multiple myeloma. Hematology and Transfusiology. Russian journal (Gematologiya i transfusiologiya) 2016;61(1, Suppl.2): 1–24. (In Russ.) doi: 10.18821/0234-5730-2016-61-1

17. Russian clinical recommendations on diagnostic and treatment of lymphoproliferative disorders under the leadership of prof. I.V. Poddubnaya, prof. B.G. Savchenko. 2016. Available at: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf

18. Dimopoulos MA, Sonneveld P, Leung N et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016;34(13):1544–1557. doi: 10.1200/JCO.2015.65.0044

19. Clinical recommendations on investigation and treatment of patients with chronic lymphocytic leukemia (2014). Group of authors under the leadership of prof. V.G. Savchenko, prof. I.V. Poddubnaya. Available at: https://blood.ru/documents/clinical%20guidelines/26.%20klinicheskie-rekomendacii-2014-xll.pdf

20. Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569

21. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978;64(5):814–826

22. Vardi A, Dagklis A, Scarfo L et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 2013;121(22):4521–4528. doi: 10.1182/blood-2012-12-471698

23. Kyle RA, Benson J, Larson D et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 2009;9(1):17–18. doi: 10.3816/CLM.2009.n.002

24. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85(10):945–948. doi: 10.4065/mcp.2010.0520

25. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108 (8):2520–2530. doi: 10.1182/blood-2006-03-001164

26. Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018;132(14):1478–1485. doi: 10.1182/blood-2018-04-839480

27. Gertz MA. Waldenstrom macroglobulinemia: 2018 update on diagnosis, risk stratification, and management. Am J Hematol 2018;1–11. doi: 10.1002/ajh.25292

28. Fish R, Pinney J, Jain P et al. The Incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010;5(11):1977–1980. doi: 10.2215/CJN.00650110

29. Matsushita K, van der Velde M, Astor BC et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet 2010;375(9731):2073–2081

30. Smirnov AV, Dobronravov VA, Kayukov IG. Сardiorenal continuum, pathogenetical grounds of preventive nephrology. Nephrology (SaintPetersburg) 2005;9(3):7–15. (In Russ.) doi: 10.24884/1561-62742005-9-3-7-15

31. Thomas B, Matsushita K, Abate KH et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 2017;28(7):2167– 2179. doi: 10.1681/ASN.2016050562

32. van der Velde M, Matsushita K, Coresh J et al. Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341–1352

33. Hui X, Matsushita K, Sang Y et al. CKD and cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study: Interactions with age, sex, and race. Am J Kidney Dis 2013; 62: 691–702

34. Kyle RA, San-Miguel JF, Mateos MV, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2014;28(5):775–790. doi: 10.1016/j.hoc.2014.06.005

35. Buxbaum JN, Hurley ME, Chuba J, Spiro T. Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med 1979;67(5):867–878

36. Benson MD. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheum 1986;29(5):683–687

37. Vaxman I, Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-ChainAmyloidosis. Acta Haematol 2019;141(2):93–106

38. Zakharova EV, Stolyarevich ES. Chemotherapy for renal AL amyloidosis: treatment results and outcomes in 49 patients from a single center. Clinical Practice 2016;13(1):11–18

39. Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122(22):3583– 3590. doi: 10.1182/blood-2013-05-495929

40. Heilman RL, Velosa JA, Holley KE et al. Long-term follow-up and response to chemotherapy in patients with light-chain depositiondisease. Am J Kidney Dis 1992;20(1):34–41

41. Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015; 88: 1135–1143

42. Gavriatopoulou M, Musto P, Caers J et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018; 32(9):1883–1898. doi: 10.1038/s41375-018-0209-7

43. Ziogas DC, Kastritis E, Terpos E et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leuk Lymphoma 2017;58(8):1832–1839. doi: 10.1080/10428194.2016.1267349

44. Nasr SH, Markowitz GS, Stokes MB et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65(1):85–96

45. Nasr SH, Snyder RW, Bhagat G, Markowitz GS. Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney Int 2007;71(2):93

46. Herrera GA, Joseph L, Gu X et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004;128(8):875–879

47. Ciocchini M, Arbelbide J, Musso CG. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. Int Urol Nephrol 2017;49(12):2171–2175. doi: 10.1007/s11255-017-1594-y

48. Kanzaki G, Okabayashi Y, Nagahama K et al. Monoclonal Immunoglobulin Deposition Disease and Related Diseases. J Nippon Med Sch 2019;86(1):2–9. doi: 10.1272/jnms.JNMS.2019_86-1

49. Caravaca-Fontan F, Gutierrez E, Delgado Lillo R, Praga M. Monoclonal gammopathies of renal significance. Nefrologia 2017;37(5):465–477. doi: 10.1016/j.nefro.2017.03.012

50. Mehtat Unlu Ş, Ozsan H, Sarıoğlu S et al. The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance. Turk J Haematol 2017;34(4):282–288. doi: 10.4274/tjh.2017.0197

51. Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013; 88(11):1284– 1293. doi: 10.1016/j.mayocp.2013.08.002

52. Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87(4):698–711. doi: 10.1038/ki.2014.408

53. Available at: https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1815409370

54. Sethi S, Rajkumar SV, D’Agati VD. The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol 2018;29(7):1810–1823. doi: 10.1681/ASN.2017121319

55. Larsen CP, Messias NC, Walker PD et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015;88(4):867–873. doi: 10.1038/ki.2015.195

56. Nasr SH, Fidler ME, Said SM. Paraffin Immunofluorescence: A Valuable Ancillary Technique in Renal Pathology. Kidney Int Rep 2018;3(6):1260–1266. doi: 10.1016/j.ekir.2018.07.008

57. Messias NC, Walker PD, Larsen CP et al. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015;28(6):854–860. doi: 10.1038/modpathol.2015.1

58. Alexander MP, Dasari S, Vrana JA et al. Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis 2018; 72(3):325–336. doi: 10.1053/j.ajkd.2018.03.017

59. Nasr SH, Vrana JA, Dasari S et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep 2017;3(1):56–64. doi: 10.1016/j.ekir.2017.07.017

60. Herrera GA, Sanders PW, Reddy BV. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain–related renal diseases. Ultrastruct Pathol 1994;18:401–416

61. Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renaldisease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130(2):165–169

62. Royal V, Quint P, Leblanc M et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol 2015;26(4):784–790. doi: 10.1681/ASN.2014050481

63. Leung N, Barnidge DR, Hutchison CA et al. Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Clin Chem Lab Med 2016;54(6):929–937. doi: 10.1515/cclm-2015-0994

64. Rosner MH, Edeani A, Yanagita M et al. Paraprotein–related kidney disease: diagnosing and treating monoclonal gammopathy of renal significance. Clin J Am Soc Nephrol 2016;11(12): 2280–2287. doi: 10.2215/CJN.02920316

65. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91(9):947– 956. doi: 10.1002/ajh.24433

66. Pasquali S, Iannuzzella F, Corrandini M et al. A novel option for reducing free light chains in myeloma kidney: Supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 2015;28(2):251–254

67. Pendon-Ruiz de Mier MV, Alvarez-Lara MA et al. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Nefrologia 2013;33(6):788–796

68. Mene P, Giammarioli E, Fofi C et al. Serum free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res 2018;43(4):1263– 1272

69. Sayed RH, Wechalekar AD, Gilbertson JA et al. Natural history and outcome of light chain deposition disease. Blood 2015;126(26):2805– 2810. doi: 10.1182/blood-2015-07-658872

70. Decourt A, Gondouin B, Delaroziere JC et al. Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis. Clin J Am Soc Nephrol 2016; 11(3):431–441. doi: 10.2215/CJN.06290615

71. Abudayyeh AA, Lahoti A, Salahudeen AK et al. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 2014;85(5):1002–1004. doi: 10.1038/ki.2014.29

72. Cohen EP, Krzesinski JM, Launay-Vacher V, Sprangers B. Onconephrology: Core Curriculum 2015. Am J Kidney Dis 2015;66(5):869– 883. doi: 10.1053/j.ajkd.2015.04.042

73. Cosmai L, Porta C, Perazella MA et al. Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant 2018;33(9):1503–1510. doi: 10.1093/ndt/gfy188

74. Capasso A, Benigni A, Capitanio U et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int 2019; article in press. doi: 10.1016/j.kint.2019.04.043